Leipzig, Germany, November 18, 2024 –(PR.com)– XOrigin and Sciospec have announced a strategic collaboration to advance bioanalytical diagnostic tools by combining their respective technologies. XOrigin, known for its flexible thin-film microsensors, will integrate its expertise with Sciospec’s precision in electrochemical and electrophysiological measurement, creating a platform that aims to enhance real-time diagnostics and provide new insights into physiological processes.
The collaboration will be based on their innovative Micro-Electro-Physio (MEP) Sensing technology, which merges XOrigin’s flexible electrode designs with Sciospec’s high-sensitivity measurement systems. According to Dr. Xin Liang, CEO of XOrigin, this partnership has the potential to drive significant advancements in diagnostics: “By joining forces with Sciospec, we’re aiming to create tools that could transform the landscape of healthcare diagnostics.”
Sebastian Wegner, CEO of Sciospec, highlighted the partnership’s cross-border collaboration: “Bringing together German and Chinese expertise through this partnership allows us to leverage both countries’ innovative strengths. We see this as an opportunity to develop solutions that can contribute broadly to medical research and healthcare applications.”
The MEP technology aims to enable new levels of precision and adaptability across various diagnostic applications, including immune response monitoring, molecular diagnostics, and blood analysis. Additionally, the technology is expected to support a deeper understanding of disease mechanisms and enhance the evaluation of drug efficacy, creating broader applications for healthcare practitioners and researchers. The companies believe their joint efforts could open new opportunities in diagnostics by capturing dynamic biological signals with greater accuracy and reliability.
For further details about the partnership and upcoming product developments, please contact:
Sebastian Wegner
Sciospec GmbH
s.wegner@sciospec.de
www.sciospec.com
